Compare CRSP & SR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRSP | SR |
|---|---|---|
| Founded | 2013 | 1857 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil/Gas Transmission |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.9B |
| IPO Year | 2016 | N/A |
| Metric | CRSP | SR |
|---|---|---|
| Price | $56.49 | $81.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 10 |
| Target Price | $71.50 | ★ $87.00 |
| AVG Volume (30 Days) | ★ 1.7M | 399.7K |
| Earning Date | 02-10-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 4.02% |
| EPS Growth | N/A | ★ 4.30 |
| EPS | N/A | ★ 4.37 |
| Revenue | $38,337,000.00 | ★ $2,476,400,000.00 |
| Revenue This Year | N/A | $13.96 |
| Revenue Next Year | $718.51 | $9.43 |
| P/E Ratio | ★ N/A | $18.78 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.04 | $65.49 |
| 52 Week High | $78.48 | $91.11 |
| Indicator | CRSP | SR |
|---|---|---|
| Relative Strength Index (RSI) | 51.43 | 39.09 |
| Support Level | $53.37 | $80.87 |
| Resistance Level | $60.73 | $84.60 |
| Average True Range (ATR) | 2.33 | 1.44 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 47.39 | 16.91 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Spire Inc. is the holding company for Spire Missouri, Spire Alabama, other gas utilities, and gas-related businesses, focused on growing organically, investing in infrastructure, and advancing through innovation. Its three segments are Gas Utility, Gas Marketing, and Midstream. The Gas Utility segment is the core business and includes Spire Missouri, Spire Alabama, and Spire EnergySouth. The Gas Marketing segment includes Spire Marketing, which provides non-regulated natural gas services across the U.S. The Midstream segment includes Spire Storage, Spire STL Pipeline, and Spire MoGas Pipeline. The majority of revenue comes from Gas Utility.